Medivir: Strong Interim Readout from Fostrox - Redeye
Redeye comments on the strong results from the first interim readout of fostrox’ phase Ib/IIa study in liver cancer with six patients. We raise our base case.
ANNONS
Redeye comments on the strong results from the first interim readout of fostrox’ phase Ib/IIa study in liver cancer with six patients. We raise our base case.